On March 14, 2023 AbCellera (Nasdaq: ABCL) reported two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19 (Press release, AbCellera, MAR 14, 2023, View Source [SID1234628733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized design of T-cell engagers for cancer targets. Additionally, AbCellera will present data on the discovery and characterization of antibodies against MAGE-A4, a validated peptide-MHC (pMHC) target for cancer treatment. Together, these two presentations illustrate how AbCellera’s CD3 panel integrates with its antibody discovery and development engine to streamline T-cell engager development.

Details on AbCellera’s poster presentations at AACR (Free AACR Whitepaper) are as follows:

Title: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies
Abstract Number: 1886
Date and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m. ET

Title: Breaking barriers to access intracellular targets with T-cell engagers: Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC
Abstract Number: 1891
Date and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m. ET

On March 14, 2023 Orum Therapeutics, Inc. ("Orum"), a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), reported that it will present new preclinical data for its ORM-5029, ORM-6151, and PD-1-Cbl-b programs in three separate presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 taking place April 14-19 in Orlando (Press release, Orum Therapeutics, MAR 14, 2023, View Source [SID1234628732]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ORM-5029 is a potential first-in-class targeted protein degrader therapy currently in a Phase 1 clinical trial for HER2-expressing breast cancer. ORM-6151 is currently in the IND-enabling stage for CD33-positive hematologic malignancies, such as acute myeloid leukemia (AML). Orum’s PD-1-Cbl-b immuno-oncology program utilizes a novel approach designed to deliver proprietary Cbl-b inhibitors specifically to PD-1-expressing exhausted T cells, while blocking PD-1/PD-L1 interaction. This strategy is expected to limit systemic exposure of Cbl-b inhibitors and minimize c-Cbl inhibition that can lead to off-target toxicity.

Presentation Details

Poster Title: Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader
Date and Time: Monday April 17, 9:00 AM – 12:30 PM ET
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers for Elucidation of Tumor Biology and Metastasis
Session Location: Section 38
Poster Board Number: 21
Abstract number: 2118

Poster Title: ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML
Date and Time: Monday, April 17, 1:30PM – 5:00PM ET
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Delivery Systems
Session Location: Section 15
Poster Board Number: 3
Abstract number: 2700

Poster Title: A novel antibody-enabled dual precision targeted protein stabilization (TPS²) that augments anti-tumor immune response by targeting CBL-B inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
Date and Time: Tuesday Apr 18, 9:00 AM – 12:30 PM ET
Session Category: Clinical Research Excluding Trials
Session Title: Immunomodulatory Agents and Interventions
Session Location: Section 40
Poster Board Number: 22
Abstract number: 4436

About Orum’s GSPT1 Platform Using the TPD² Approach

Orum’s GSPT1 platform uses the company’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach to build novel targeted protein degraders combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-specific TPDs for the treatment of cancer. Orum has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to cancer cells and degrade the intracellular target protein GSPT1 and cause tumor cell death.

About Orum’s TPS² Approach

Orum’s Dual-precision Targeted Protein Stabilization (TPS²) approach combines novel targeted protein inhibitors with the precise cell delivery mechanism of antibodies to increase the levels of intracellular target proteins in a cell-type-specific manner for oncology and immuno-oncology. The first program applying the TPS² approach is a Cbl-b inhibitor (Cbl-bi) conjugated to anti-PD-1 antibody. By delivering Cbl-bi specifically to exhausted T cells, the conjugate restores effector T cell function where PD-1 checkpoint blockade alone is insufficient, while also enabling T cells to overcome the immunosuppressive mechanisms in a tumor microenvironment.

On March 14, 2023 Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, reported that the company will present two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, being held in Orlando, Florida, April 14-19, 2023 (Press release, Asher Biotherapeutics, MAR 14, 2023, View Source [SID1234628731]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A poster highlighting Asher Bio’s lead immunotherapy candidate, AB248, a CD8+ T cell-selective IL-2, will be featured as a clinical trial in progress for the ongoing Phase 1a/b study of AB248 alone and in combination with pembrolizumab in patients with advanced solid tumors who failed prior standard of care treatments. (NCT05653882).

Asher Bio will also present new preclinical data for CAR-T-specific IL-2 and IL-21 therapies demonstrating highly selective delivery of cytokine support to CAR-T cells and enhanced anti-tumor activity via distinct mechanisms. Asher Bio has engineered cis-targeted cytokine fusion molecules that specifically activate only CAR-T cells by delivering either IL-2 or IL-21, while exhibiting minimal activity on bystander cells, to offer the potential for greater activity and durability of CAR-T cell therapy.

Details of the poster presentations are as follows:

Title: An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
Authors: Elizabeth I. Buchbinder, M.D., David R. Spigel, M.D., Constantine Albany, M.D., Michael Chisamore, Ph.D., Kelly D. Moynihan, Ph.D., Xiaohan Liu, Pharm. D., Christopher DelNagro Ph.D., Matt Axt, Andrea Pirzkall, M.D.
Session Title: Phase I and First-in-Human Clinical Trials in Progress
Session Date & Time: Tuesday, April 18, 2023, 1:30 – 5:00 p.m. ET
Poster Section: 46
Poster Board Number: 13
Abstract Number: CT250

Title: Engineered cell surface tag-targeted IL-2 and IL-21 selectively and safely enhance CAR-T anti-tumor activity via different mechanisms
Authors: Nathan D. Mathewson, Ph.D., Wei Chen, Ph.D., Paul Bessette, Ph.D., Sara Sleiman, M.D., Meghana Sukthankar, Kelly D. Moynihan, Ph.D., Chris Kimberlin, Ph.D., Terrence Park, Audrey Hollingsworth; Saar Gill, M.D., Ph.D., Andy Yeung, Ph.D., Ivana Djuretic, Ph.D.
Session Title: Immunomodulatory Agents and Interventions 2
Session Date & Time: Monday, April 17, 2023, 9:00 a.m. – 12:30 p.m. ET
Poster Section: 24
Poster Board Number: 19
Abstract Number: 1847

The abstracts are now available on the AACR (Free AACR Whitepaper) conference website.

On March 14, 2023 Flare Therapeutics Inc., a private biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, reported that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida (Press release, Flare Therapeutics, MAR 14, 2023, View Source [SID1234628730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details are as follows:

Abstract Title: Discovery of FX-909, a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor, to treat patients with the luminal subtype of advanced urothelial cancer (UC)
Session Category: Drug Development Track Special Session
Session Title: New Drugs on the Horizon: Part 2
Presenter: Robert Sims, Ph.D., Chief Scientific Officer and Co-founder of Flare
Date/Time: Sunday, April 16, 2023 from 3:00 to 4:30 p.m. ET
Location: Tangerine Ballroom 2, Convention Center

Flare is advancing FX-909 into the clinic in patients with advanced urothelial cancer (UC). FX-909 is a potent, selective, small molecule inhibitor of the PPARG lineage transcription factor. In pre-clinical models, FX-909 displays meaningful PPARG target gene silencing in UC cell lines as well as tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models.

On March 14, 2023 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, reported the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR (Free AACR Whitepaper) Annual Meeting, held April 14-19, 2023, in Orlando, Florida (Press release, Repare Therapeutics, MAR 14, 2023, View Source [SID1234628729]). An AACR (Free AACR Whitepaper) assigned discussant of the presentation will interpret the data in this plenary session. Two poster presentations for RP-6306, a first-in-class, oral PKMYT1 inhibitor, will also be introduced in the Clinical Research session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are as follows:

Title: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
Presenter: Dr. Timothy Yap
Session Category: Clinical Trials Plenary Session
Session Title: Novel Biomarker-driven Molecularly Targeted Therapy Trials
Date and Time: Tuesday Apr 18, 2023 11:15 AM – 11:30 AM
Published Abstract Number: 23-LB-9625-AACR

Title: Characterization of CCNE1 amplifications and associated genomic features in ovarian and uterine cancers
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 5
Date and Time: Tuesday Apr 18, 2023 1:30 PM – 5:00 PM
Location: Poster Section 37
Poster Board Number: 19
Published Abstract Number: 5469

Title: Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 2
Date and Time: Monday Apr 17, 2023 9:00 AM – 12:30 PM
Location: Poster Section 39
Poster Board Number: 6
Published Abstract Number: 2132

About Repare Therapeutics’ SNIPRx Platform

Repare’s SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.